Not Yet RecruitingPhase 2

N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

Norway270 participantsStarted 2026-08-15

Plain-language summary

The goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside. The main questions it aims to answer are: * Does drug nicotinamide riboside slow the progression of Alzheimer disease as measured by the Clinical Dementia Rating scale. * What medical problems do participants have when taking drug nicotinamide riboside? Researchers will compare drug nicotinamide riboside to a placebo (a look-alike substance that contains no drug) to see if nicotinamide riboside works to treat early Alzheimer disease. Participants will: * Take drug nicotinamide ribosie or a placebo every day for 24 months * Visit the clinic once every 26 weeks for checkups and tests

Who can participate

Age range

50 Years – 85 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis Early clinical AD, e.g. Stage 3 MCI or Stage 4 (mild AD dementia), as defined by the FDA, 2024. * Biomarker evidence consistent with AD neuropathologic change, defined by CSF markers, i.e. Aβ42 \< 1030 ng/L and P-tau181/Aβ42 \> 0,023 ng/L and/or T-tau/Aβ42 \> 0,28 ng/L\* or AD amyloid biomarker (as determined either by visual reading of amyloid PET scans using an approved ligand * Diagnosed with AD within 2 years from baseline. * Capacity to provide written informed consent for study participation defined as Montreal Cognitive Assessment (MoCA) score ≥ 16 or Mini Mental State Evaluation (MMSE) score ≥ 20. MMSE or MoCA must have been performed within 6 months prior to baseline. If there is any doubt regarding the participants capacity to give informed consent, this will be determined by an evaluation by a consultant clinician who is not associated with the N-AD study. * Global CDR(33) 0.5-1 (inclusive) at enrollment. * Age 50 to 85 years (inclusive) at the time of enrollment. * A study partner with sufficient contact to be able to provide data on ADLs and assist the participant in study drug administration. - * Cholinesterase inhibitors and memantine can be used if stable for 8 weeks prior to baseline visit. Exclusion Criteria: * Diagnosis of dementia other than probable AD. * Abundant vascular pathology, i.e. Fazekas \>2. or \>3 lacunar infarcts, stroke involving a major vascular territory, severe small vessel, or white matter disease * More…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial is testing nicotinamide riboside, which is a form of vitamin B3, as a possible disease-modifying treatment for Alzheimer's — can you explain what 'disease-modifying' means in this context, and how that differs from treatments that just manage symptoms?
2Since this is a Phase 2 trial, what does that tell us about how much is already known about whether nicotinamide riboside is safe and effective for people with Alzheimer's disease?
3The trial runs for two years and measures disease severity using something called the CDR sum of boxes — is that a meaningful measure of day-to-day functioning, and what would it mean for a participant if their score doesn't improve over that time?
4The trial isn't recruiting yet — given where things stand with my diagnosis right now, would it make more sense to start a standard treatment first, and is there a point at which I might no longer be eligible to consider joining when it does open?
5Are there any other ongoing or available treatments I should be pursuing in the meantime, and would participating in this trial affect my ability to try other options if something better comes along during those two years?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Disease severity assessed by the Clinical Dementia Rating scale (CDR) sum of boxes.

Timeframe: From baseline to the end of treatment at 104 weeks.

Trial details

NCT IDNCT07741071

SponsorHaukeland University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-04-30

Contact for this trial

Kristoffer Haugarvoll, MD, PhD

47-55975045 kristoffer.haugarvoll@helse-bergen.no

View on ClinicalTrials.gov More Alzheimer Disease (AD) trials